{"name":"Adaptimmune Therapeutics","slug":"adaptimmune","ticker":"ADAP","exchange":"NASDAQ","domain":"adaptimmune.com","description":"Adaptimmune Therapeutics is a biotechnology company focused on developing cell therapies for cancer treatment. The company's pipeline includes several autologous genetically modified T-cell therapies targeting various tumor antigens. Adaptimmune has a strong presence in the cell therapy and immuno-oncology sectors, with multiple clinical-stage programs. However, the company has faced challenges in recent years, including the discontinuation of several programs and a decline in its stock price.","hq":"Abingdon, Oxfordshire, UK / Philadelphia, PA","founded":0,"employees":"","ceo":"Adrian Rawcliffe","sector":"Cell Therapy / Immuno-Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$220M","metrics":{"revenue":178032000,"revenueGrowth":195.3,"grossMargin":0,"rdSpend":149060000,"netIncome":-70814000,"cash":245963000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Adaptimmune Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Adaptimmune reported a net loss of $44.4 million for the fourth quarter of 2023 and a net loss of $184.8 million for the full year. The company's revenue was $1.4 million for the quarter and $4.3 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Adaptimmune Announces Collaboration with GSK to Develop T-Cell Therapies for Cancer","summary":"Adaptimmune announced a collaboration with GSK to develop T-cell therapies for cancer. The collaboration will focus on the development of T-cell therapies targeting various tumor antigens.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Adaptimmune Announces Update on Phase 1 Clinical Trial of MAGEA10ᶜ⁷⁹⁶T","summary":"Adaptimmune announced an update on its Phase 1 clinical trial of MAGEA10ᶜ⁷⁹⁶T, a T-cell therapy targeting the MAGEA10 antigen. The trial is ongoing and has enrolled patients with various types of cancer.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxNSl9JSmp2Y0xGTk9qNWF0MjJDM09vVjBQSS1LdzNUSzcyd0U5TEp2c3FKYnBxWFBsLXBpRldvb2hIRFBfU1V6alFnSWlfeVBrU3Y0QjRQN0ZlMWlDV3pVdTllS2JpQnVUU25CalUwMlp3Y2tYR29MLVM3YkxHSWMwckNXWndlUUQ5aG4tQUNCNGdVQjFDR3pCdXpVNDhSQmhDNXFmTzdsNnpJM3NiVktTTXdMZy1BeGZia3VwUWg3YXhDV1lzemFMbnVDME5NT09KODVaVEE5UmVwZjBaQWh2d19ydEVhU1dqS1pMN2wtZHgzclVja0FwNFJWWTA0RXoyS0ZSdkVETDBJNEVZOFNr?oc=5","date":"2025-10-20","type":"pipeline","source":"FinancialContent","summary":"Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures - FinancialContent","headline":"Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures","sentiment":"neutral"},{"date":"2025-10-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUk9abFBlN2VyTVZpYk5LeHh4OXhQRXdUY012d3R0bzdVOFVKVThtWVYyTFYybVdzYmJrY09FRWZuY2hjZmhHVTViTUJ5N2JYQWk2R0FKcVd2UVZZYmZURW5kQXBjd0JrWnhDVUR4QlNXTzZCNmdNQm5rUkY0b0lySnZHVXVPM24yQVNHdlEyZjAzWldpVVJTV214RWUweXdMMDhXUnZFV3JzZw?oc=5","date":"2025-10-08","type":"pipeline","source":"TechStock²","summary":"Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? - TechStock²","headline":"Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? - TechStock²","sentiment":"neutral"},{"date":"2025-09-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxPNU9Fdk92eGZlcWxVR2RBcWNCdTdzb0g2YUJJQmtRNlFreFlYV2NvdWdLeHRGV20wTW8ybXZkQ0txWFR4Q0RjOGsyNmZvNk5sZlVYWXZqYkExVHBUZThKMkRqUmJ2R2hVVWIxSC1YMXRrdGUyeFoydEJKaW9jNjVPUWs0S2pCZFdnRnUxM0ZYOHRnWEx4Zy1tVnRlYnVLSksyTUxuak9YY3NJbU50VnJDRWxoWFZqNHBVNjhaWGZhYUlSUHJjTXlUeVR0eFJEbUswT0NF?oc=5","date":"2025-09-19","type":"regulatory","source":"Benzinga","summary":"Why FedEx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket - (ADAP), AGM Group Holdin - Benzinga","headline":"Why FedEx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket - (ADAP), AGM Group Holdin","sentiment":"neutral"},{"date":"2025-09-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-09-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-08-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNeTc5b3JQbzJrTU9hOWRKcHZhNnR5T0JGVk1NR21zUEQ0VWJjdGNGemNjQ3JwS3JvcjVZQVJ1b2VtcmJ1clpkU3V3Mi15Z2lhbldwdnlxaDJURVdaUmcxS1lfcm1DaU9PNVRDcWNzMjQ0ZHhvREZWWUxKa0tBWWRrVHVDT01EUWJkVTVQbjlCVUdKeUcyaHAtUjM1bGRFQk5JejU1dnpSbFRfQQ?oc=5","date":"2025-07-29","type":"pipeline","source":"GuruFocus","summary":"Adaptimmune (ADAP) Downgraded to Neutral After Asset Sale - GuruFocus","headline":"Adaptimmune (ADAP) Downgraded to Neutral After Asset Sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1WVUpua0ZueEp1eDRPRTVwdlMtUkZsX2xHRzI2RTZlMEtkQ25NdlVuQVJfSG1hNkRLZjdkSGFPcVNjSm93ZFhVTWtHSWVXdThqWmRr?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"ADAP Stock Price, News & Analysis - Stock Titan","headline":"ADAP Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQSEI4M1pqMVdGdWRoUlBBcFVyWk5Xb3VlUmh1R0x3YlBiaGFJTkl1WG5yS0Z5ODRQTWk1R0NZS1V3Y1NEa1RpdTZiX25neHh3cHJxVUR4UmNVMklFSTg3ekFUaFFnSDYxdFZKSVRueVhUNTBjNGxqVndPMDlRdGFiSmd0ajhLSmpTQTdHck54MFhrNzBGMDdCTkNSamViY0RRbU9LSUlqTzJ4YnE3QzZHaHdDQVFsTGZpWlBMQkxqSno?oc=5","date":"2025-03-20","type":"pipeline","source":"Fierce Biotech","summary":"UPDATE: Adaptimmune, after bringing cell therapy to market, questions viability and defunds 2 preclinical programs - Fierce Biotech","headline":"UPDATE: Adaptimmune, after bringing cell therapy to market, questions viability and defunds 2 preclinical programs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOMnZCLVA0LU1ILWgyb1RaUDB1TWl3U09lNmE5UG42RldBeFg0eWJHd2twWE9Xdl9TMzNrcWFLV0hERmhLVmJlS05UTGQtYThsQlFuLVVJZ1lYS3lqc1VUVEhPclJRaXVWLTd4amtFWnNKeEhSU1g3YWxLak1YdDRDbHZobUtLbkJZd2FHWHRGd1FITFJBc044a3A3cmJnLXFMZExhaTB0Y1VSRVlj?oc=5","date":"2024-09-12","type":"pipeline","source":"Seeking Alpha","summary":"Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions (NASDAQ:ADAP) - Seeking Alpha","headline":"Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions (NASDAQ:ADAP)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNbzk4ZmxST2N2TXVwdmlkUE95ejdVbElSTlRid0lBR1Z6SU1la25vT2tHYmttbEhKenpGUHhjQURTOE10SkVQQlgyY1A0SzBrT0pRNi1TS0ZUbHRDNlFRTHE0clFGclRvV2N0OW1VX0JXanNiWUVJR0NsUVhqbjlETGp5VXl0RS13em00OWNmc3ZLamVYNWZfR3FnWkNJQzQ?oc=5","date":"2023-03-06","type":"deal","source":"BioPharma Dive","summary":"Adaptimmune acquires struggling cell therapy rival following layoffs - BioPharma Dive","headline":"Adaptimmune acquires struggling cell therapy rival following layoffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPa1gtck4yNW0wdHBaMW5qZWVsZndKbmZYdGFsaXBqaUFSZS1UdDlPNXJfcGRMRnZRLW0tWXppZFRBN1JlczVWU3Q0elFROUpvSjNmLV9Td0c5MnJtajB4RGYtMlJNSU1iRXo5S2NyOUlrX3NXcHo2VjdLRWY4S3c5eVFkTFVzc0dVWS1nNFg0d1pDa1U?oc=5","date":"2023-03-06","type":"deal","source":"The Pharma Letter","summary":"Adaptimmune and TCR² Therapeutics plan merger - The Pharma Letter","headline":"Adaptimmune and TCR² Therapeutics plan merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNTlJsbnNBWE9QRXZDenlnNXhNZjZjTzhrSW5zVk9TM2xBYlRvaUpaWW4tYzlwd0lNeHRmbjAxTExLTjdKZDBoVGNXbkhCWC0wODF3NmV5R19nOUw1X1hRZERWMUtaNVlWaFpjSC1BNkM1RjhaeHZ3QlF4ang2WVBOOUh1eThNUVJBSHNxcnRhRHJiS2N6LWNCOV80TUNfZnpqOGM1TmZaUG9FRmxwOWZ2eTByOA?oc=5","date":"2022-08-22","type":"pipeline","source":"The Wall Street Transcript","summary":"Interview with the CEO: Adaptimmune Therapeutics PLC (NASDAQ:ADAP) - The Wall Street Transcript","headline":"Interview with the CEO: Adaptimmune Therapeutics PLC (NASDAQ:ADAP)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Novartis"],"therapeuticFocus":["Cell Therapy","Immuno-Oncology"],"financials":{"source":"sec_edgar","revenue":178032000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":178032000,"period":"2024-12-31"},{"value":60281000,"period":"2023-12-31"},{"value":60281000,"period":"2023-12-31"},{"value":27148000,"period":"2022-12-31"},{"value":27148000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":149060000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-70814000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":245963000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}